Learn to simulate stock prices with Excel and gain predictive power over market trends. Our step-by-step guide enhances your ...

Microsoft's spreadsheet program can do way more than you might imagine. These are the hacks and tricks you need to know.

Learn the difference between Excel COUNT and COUNTA, plus TEXTBEFORE and TEXTAFTER tricks, so you clean text and totals with ...

Some of the citations that underpin the science in the White House’s sweeping “MAHA Report” appear to have been generated using artificial intelligence, resulting in numerous garbled scientific ...

Ramanujan’s elegant formulas for calculating pi, developed more than a century ago, have unexpectedly resurfaced at the heart of modern physics. Researchers at IISc discovered that the same ...

Cell therapy company Link Cell Therapies is launching with $60 million and a mission to develop potent CAR-T therapies that go after a range of tumors while avoiding patients' healthy tissue. The ...

A schematic illustration of how GigTIME can take a hematoxylin and eosin (H&E) pathology slide and use AI to virtually identify a suite of proteins that would otherwise require multiplex ...

When Steelers coach Mike Tomlin disclosed on Sunday morning that quarterback Aaron Rodgers would not play in his Soldier Field swan song, Tomlin made it clear that he expects Rodgers to return for ...

Durham leaders have approved a rezoning request that will allow Research Triangle Park to become more of a destination hub. Durham County Board of Commissioners voted unanimously on Monday to amend ...

Shares of Agios Pharmaceuticals AGIO tanked about 51% on Wednesday after it reported mixed top-line results from the phase III RISE UP study, which evaluated orally administered Pyrukynd (mitapivat) ...

In its mission to grow the reach of its pyruvate kinase (PK) activator Pyrukynd (mitapivat), Agios Pharmaceuticals has come up short of producing an unequivocal win in the key indication of sickle ...

Third Arc Bio is paying $5 million upfront to use Adagene’s tech in hopes of creating two new masked T-cell engagers. Down the line, Adagene could make up to $840 million in development and commercial ...